Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020
- Webinar Scheduled for
5:30 AM PT/ 8:30 AM ET
David Chang, M.D., Ph.D. – President, Chief Executive Officer and Co-Founder of Allogene Rafael Amado, M.D. – Executive Vice President of Research & Development and Chief Medical Officer of Allogene
- Sattva S. Neelapu, M.D. – Professor,
Department of Lymphoma/Myelomaat The University of Texas MD Anderson Cancer Centerin Houston, Texas
Please register for the webinar on the Company's website at www.allogene.com under the Investors tab in the News and Events section (https://ir.allogene.com/events) or by clicking the following link directly.
The webinar will be available as a live event only and the materials presented will be available on the Allogene website prior to the start of the event.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop AlloCAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the
AlloCAR T™ is a trademark of
Allogene Media/Investor Contact:
Chief Communications Officer
Source: Allogene Therapeutics, Inc.